The peptide relaxin has gained considerable attention as a new vasoactive drug, largely through its beneficial therapeutic effects in cardiovascular disease. In this study, we tested the hypothesis that relaxin treatment alleviates systemic vascular dysfunction characteristic of hypertensive diseases of pregnancy. We investigated vascular effects and mechanisms of relaxin action in (i) pregnant relaxin-deficient (Rln −/− ) mice with enhanced responses to angiotensin II (AngII) and (ii) arteries pre-incubated ex vivo in trophoblast conditioned media (TCM) to induce endothelial dysfunction. Pregnant Rln −/− mice received 0.5 μg/h recombinant human H2 relaxin (rhRLX: n = 5) or placebo (20 nM sodium acetate; n = 7) subcutaneously via osmotic minipumps for 5 days prior to gestational day 17.5. This treatment protocol significantly reduced AngII-mediated contraction of mesenteric arteries and increased plasma 6-keto prostaglandin F 1α . These vascular effects were endothelium independent and likely involve smooth muscle-derived vasodilator prostanoids. In the second study, mesenteric arteries were incubated ex vivo for 24 h at 37
depending on duration of relaxin treatment and type of vascular dysfunction. Overall, our data suggest that relaxin is a potential therapeutic to alleviate maternal systemic vascular dysfunction associated with hypertensive diseases in pregnant women.
INTRODUCTION
Early maternal vascular adaptations to pregnancy are paramount to the survival and development of the fetus and maternal health. During pregnancy, the maternal systemic vasculature becomes refractory to the vasoconstrictor actions of angiotensin II (AngII) [1] [2] [3] , the thromboxane A 2 mimetic U46619 [4] , and phenylephrine [5] . The maternal vasculature also exhibits enhanced response to and production of the endothelium-dependent vasodilators nitric oxide (NO), prostacyclin (PGI 2 ), and endothelium-derived hyperpolarization (EDH) [6] [7] [8] . Alterations in the critical balance between vasodilators and vasoconstrictors can result in endothelial dysfunction, a symptom of many vascular diseases including fetal growth restriction, pregnancy-induced hypertension, and preeclampsia (PE) [9] . In many women with PE, there are increased levels of circulating antiangiogenic factors, soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng), and increased reactive oxygen species (ROS) generation [10] . Upregulation of these factors is linked to increased responsiveness to AngII, thromboxane A 2 , and endothelin-1 (ET-1) [11] . This proconstrictor environment is further exacerbated by angiotensin type I receptor agonistic autoantibodies, which increase sFlt-1, ROS, and constriction, implicating the renin-angiotensin system in the pathogenesis of PE [12] .
The peptide relaxin is now considered an important regulator of maternal cardiovascular adaptations to pregnancy, especially the hemodynamic changes in the renal and systemic vasculature [13] . These are largely attributed to the vasodilator effects of relaxin on small renal arteries [14] . The detrimental effects on the vasculature of a lack of circulating endogenous relaxin are best illustrated in relaxin-deficient rodents during pregnancy [3, [15] [16] [17] . Specifically, myogenic reactivity in small renal arteries is increased [17] and uterine artery remodeling is compromised [16] in pregnant rats treated with an antibody (MCA1) to neutralize circulating relaxin. Arteries of male relaxin gene knockout (Rln −/− ) mice have enhanced responsiveness to vasoconstrictors phenylephrine and U46619 [18] , increased superoxide production coupled with a reduction in NO [19] , and enhanced myogenic reactivity [20] . We also demonstrated enhanced sensitivity to both phenylephrine and AngII in the mesenteric arteries of late-pregnant Rln −/− mice [3] . This hyperresponsiveness to AngII in Rln −/− mice is endothelium independent and associated with a reduction in smooth muscle-derived vasodilator prostanoids. Exogenous relaxin has beneficial vascular effects in healthy male and nonpregnant female rodents [21, 22] . These include reductions in myogenic reactivity and enhanced agonist-mediated endotheliumdependent vasorelaxation. The underlying mechanisms of relaxin action include activation of endothelin B (ET B ) receptors and NOdependent vasodilation [23, 24] . More recently, we have shown that relaxin treatment protects the aorta of male mice from high glucose-induced endothelial dysfunction ex vivo, an effect attributed to restoration of PGI 2 production, and a reduction of ROS generation [25] . Relaxin also ameliorates tumor necrosis factor (TNF) α-induced endothelial dysfunction by increasing endothelial NO synthase (eNOS) activity [26] . These studies suggest a vasoprotective role for relaxin through its ability to correct an imbalance between vasodilators and vasoconstrictors, thereby reversing endothelial dysfunction.
Very little work has assessed the effects of exogenous relaxin treatment in pregnancy, mainly because most animals have high circulating relaxin levels. Recombinant human relaxin treatment from midpregnancy in the reduced uterine perfusion pressure rat model of PE lowered mean arterial pressure and uterine artery resistance index on gestational day 19 [27] . This was accompanied by decreases in placental prepro-ET-1, TNF-α, and circulating nitrate concentrations. However, there was no assessment of relaxin action on vascular reactivity. Therefore, the first aim of our study was to test the hypothesis that relaxin treatment reduces the endothelial dysfunction that we previously reported in the mesenteric arteries of pregnant Rln −/− mice. As these mice do not have increased sFlt-1 or hypertension [28] , they are not a model of PE. Therefore, the second aim of this study was to develop an ex vivo vascular model that more closely replicates PE-induced endothelial dysfunction. We incubated the mesenteric arteries in trophoblast conditioned media (TCM) containing high levels of sFlt-1 and sEng [29] . Since TCM incubation induced endothelial dysfunction. it was then feasible to test the hypothesis that co-incubation with relaxin would prevent the onset of this endothelial dysfunction.
MATERIALS AND METHODS

Animals
All animal experiments were approved by The University of Melbourne Animal Experimental Ethics Committee (AEEC #1212387) and conducted in accordance with the Australian Code of Practice and the National Health and Medical Research Council. This study used adult wild-type (Rln +/+ ) and Rln −/− mice bred in the School of BioSciences Animal Facility. Pregnant mice were primigravid. All mice used in this study were between 3 and 5 months of age. Mice were maintained on a 12 h light/dark cycle at 20
• C, with standard food pellets (Barastock, Victoria, Australia) and water available ad libitum. Homologous recombination in embryonic stem cells was used to disrupt the relaxin gene by deleting a region essential for biological activity and replacing it with the neomycin transferase gene [30] . Rln −/− mice were then backcrossed to a C57BL/6J background and the F14 generation relocated to the School of BioSciences. PCR analysis of genomic DNA from ear clips confirmed mouse genotypes as previously described [15] . Relaxindeficient pregnant mice were selected for the first part of this study as they do not undergo the normal pregnancy-induced reduction in vasoconstriction to AngII in the mesenteric artery [3] . These mice were also selected, as they have no circulating or locally produced relaxin during their pregnancy, making them a suitable model to investigate the effect of exogenous relaxin treatment without the confounding effects of endogenous relaxin. The length of the pubic ligament was measured in all mice with a digital vernier caliper as this is a bioassay for relaxin bioactivity [31] .
Isolation of mesenteric arteries
Mice were euthanized by 2% isofluorane and cervical dislocation. Small mesenteric arteries (first-order branches of the superior mesenteric artery) were isolated, cleared of fat and loose connective tissue, and cut into 2 mm rings. After arteries were mounted on the myograph (model 610M; Danish Myo Technology, Aarhus, Denmark), they were allowed to stabilize for 15 min before normalization, as described previously [32] .
In vivo study
Female Rln −/− mice were housed with a stud male of matched genotype overnight and checked for mating plugs the next morning. The presence of a mating plug was an indication of successful mating and was considered day 0.5 of pregnancy. On day 12.5 or 14.5 of pregnancy, Rln −/− mice were surgically implanted with an Alzet osmotic minipump (Model 1007D; flow rate: 0.5 μl/h; BioScientific Pty Ltd, Kirrawee, New South Wales, Australia) to administer recombinant human H2 relaxin (rhRLX, 0.2 or 0.5 μg/h; Novartis Pharma AG) or placebo (20 mM sodium acetate) for 3 or 5 days (n = 5-7 per treatment). These doses of rhRLX have been used previously, produce biological modifications to the reproductive tract but do not disrupt pregnancy in any way [15, 33] . They also result in circulating relaxin levels that are within a physiological range in late pregnancy. On day 17.5 of pregnancy, mice were anesthetized by isofluorane and blood samples (approximately 0.7 ml) collected by cardiac puncture before cervical dislocation. Plasma osmolality was measured using the vapor pressure osmometer (Vapro model 5600). The plasma concentration of rhRLX was measured using the Human Relaxin-2 Quantinine ELISA Kit (R&D Systems, Minneapolis, MN, USA) as per the manufacturer's instructions (samples diluted 1:200). The limit of detection was 15.6 pg/ml. 6-Keto prostaglandin F 1α (PGF 1α ) (metabolite of PGI 2 ) was also measured in the plasma using an EIA kit from Cayman Chemical (Ann Arbor, MI, USA) as per the manufacturer's instructions (samples diluted 1:2). Vascular reactivity was performed as described below.
Ex vivo study
Mesenteric arteries were isolated from female virgin wild-type mice after euthanasia and subsequently cleaned. Arteries from virgin mice were used as this removed any influence of circulating pregnancy hormones, including relaxin. Each artery was incubated for 24 h at 37
• C with 5% CO 2 in a 12-well plate containing 1 ml media.
Arteries were incubated in either control medium (50% M199, 50% DMEM) or 50% TCM (described below) with placebo (20 mM sodium acetate) or 1 nM, 10 nM, or 15 nM rhRLX (Novartis Pharma AG) (n = 6-16 mice per treatment). These are pharmacological doses of rhRLX and have been used previously in similar studies [34] . After 24 h, vascular reactivity was performed as described below [32, 35] .
Assessment of vascular reactivity
Arteries were contracted with high potassium PSS (KPSS; K + = 100 mmol/L, isoosmotic replacement of Na + with K + ). Absolute contraction to KPSS did not vary depending on treatment. Subsequently, the integrity of the endothelium was determined by submaximally preconstricting arteries with phenylephrine to ∼50% KPSS contraction, and then applying acetylcholine (ACh; 10 μmol/L) to induce relaxation. Arteries with >90% relaxation were deemed suitable for further analysis. The level of precontraction used when examining vasodilator function was kept constant across the genotypes and treatment groups. For the in vivo study, smooth muscle reactivity to vasoconstrictors was evaluated. Cumulative concentration-response curves to AngII (0.1 nmol/L to 0.1 μmol/L), ET-1 (0.1 nmol/L to 0.1 μmol/L), and phenylephrine (1 nmol/L to 10 μmol/L) were constructed. To avoid the confounding effects of tachyphylaxis, each artery was exposed to an AngII dose response curve only once. Cumulative concentration-response curves to ACh and bradykinin (BK) were not performed because the mesenteric artery of Rln −/− mice does not display impaired agonist-dependent relaxation relative to wild-type mice [3] . Responses to AngII were examined after 20 min of incubation with different AngII receptor inhibitors, including the AngII type 1 receptor (AT 1 R) antagonist irbesartan (1 μmol/L) and the AngII type 2 receptor (AT 2 R) antagonist PD123,319 (1 μmol/L). In other experiments, the influence of the endothelium on vascular smooth muscle reactivity to AngII was also evaluated in endothelium-denuded arteries. Arteries were considered to be denuded of endothelium if the response to ACh (10 μmol/L) was abolished. Denuded arteries were exposed to the soluble guanylate cyclase (sGC) inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; 10 μmol/L) before exposure to AngII to determine the influence of this pathway on the vasoconstriction. The effect of relaxin treatment on basal levels of NO release was examined through the addition of the NOS inhibitor Nω-nitro-L-arginine methyl ester (L-NAME; 200 μmol/L) in endothelium-intact and denuded rings precontracted with phenylephrine to approximately 20% KPSS, as previously described [36] .
For the ex vivo study, cumulative concentration-response curves to ACh (0.1 nmol/L to 10 μmol/L), the endothelium-independent vasodilator sodium nitroprusside (SNP; 0.1 nmol/L to 10 μmol/L), and AngII (0.1 nmol/L to 0.1 μmol/L) were constructed. Prior to exposure to ACh and SNP, arteries were precontracted with phenylephrine to ∼50% KPSS. 10 nM and 15 nM of relaxin is equivalent to 60 and 90 ng/ml, respectively. These concentrations were selected as they cause rapid vasodilation of human and rodent arteries ex vivo [34] .
Reagents for vascular reactivity studies
All drugs were purchased from Sigma-Aldrich (St Louis, MO, USA) and dissolved in distilled water, except ibersartan and ODQ, which were dissolved in DMSO as 1 mmol/L stock solution. All subsequent dilutions were in distilled water.
Trophoblast conditioned media generation
Women presenting to the Mercy Hospital for Women (Heidelberg, Victoria, Australia) gave informed written consent for collection of placental tissue. Ethical approval was obtained from the Mercy Health Human Research Ethics Committee (R11/34). Primary trophoblast cells were isolated from the placenta of normotensive women having elective caesarean section at term and cultured in DMEM GlutaMAX (Thermo Fisher Scientific, Auckland, New Zealand) for 24 h at 37
• C at 8% O 2 , as previously described [37] . Each batch of TCM was an accumulation of cultures from three to five different placentas and two batches were used for this study. Secretion of sFlt-1 and sEng was measured using ELISA kits (VEGF/R1 and Endoglin/CD105, R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions. Optical density was determined using a BioRad X-Mark microplate spectrophotometer (BioRad), and sFlt-1 and sEng levels were determined using BioRad Microplate manager 6 software.
Statistical analyses
All results are expressed as a mean ± SEM and n represents the number of animals per group. Concentration-response curves were computer fitted to a sigmoidal curve using nonlinear regression (Prism version 5.0, GraphPad Software, San Diego, CA, USA) to calculate the sensitivity of each agonist (pEC 50 ). Maximum contraction (E max ) to AngII, ET-1, and phenylephrine was measured as a percentage of contraction to KPSS. Maximum relaxation (R max ) to the endothelial agonist ACh was expressed as a percentage of the level of precontraction to phenylephrine. Group area under the curve (AUC), pEC 50 , R max , and E max values were compared within or between the single variable of treatment using one-way ANOVA with post hoc analysis using the Dunnett test or t-tests where appropriate. P < 0.05 was considered statistically significant.
RESULTS
Bioactivity of rhRLX in pregnant Rln
−/− mice rhRLX was only detected in the plasma of rhRLX-treated mice (3 days: 3.81 ± 0.41 ng/ml −1 , 5 days 10.18 ± 0.96 ng/ml −1 ). The pubic symphysis was significantly (P < 0.001) increased in both the 3 and 5-day rhRLX treatment groups compared with placebo controls (3 days: placebo 1.57 ± 0.10 mm, rhRLX 4.13 ± 0.19 mm, 5 days: placebo 1.20 ± 0.5 mm, rhRLX 4.47 ± 0.17 mm). Further evidence of rhRLX bioactivity in mice is shown by a significant reduction in plasma osmolality in the 5-day rhRLX-treated Rln −/− mice compared with placebo controls (P = 0.018; placebo 327.6 ± 1.01 mmol/kg, rhRLX 319.9 ± 2.72 mmol/kg).
Mesenteric responsiveness to vasoconstrictors after rhRLX treatment
We previously demonstrated that mesenteric arteries of relaxindeficient mice have enhanced responses to AngII in late pregnancy [3] . Therefore, we investigated whether or not rhRLX treatment could restore normal responsiveness to AngII as seen in Rln +/+ mice.
Subcutaneous rhRLX treatment for 3 days (from day 14.5 to 17.5 of pregnancy) at a dose of 0.2 μg/h did not alter vascular reactivity (sensitivity, maximal response, and AUC) of the mesenteric artery to AngII in pregnant Rln −/− mice when compared to placebo treatment ( Figure 1A , C and D, Table 1 ). However, rhRLX treatment for 5 days (from day 12.5 to 17.5 of pregnancy) at a dose of 0.5 μg/h significantly reduced the maximal response (P = 0.0002) and AUC (P = 0.0004) to AngII relative to mesenteric arteries from placebotreated mice ( Figure 1B -D, Table 1 ). Therefore, all further in vivo treatments with rhRLX were 0.5 μg/h for 5 days prior to day 17.5 of pregnancy. Subcutaneous rhRLX treatment in pregnant Rln −/− mice for 5 days did not alter vascular responses of the mesenteric artery to the other vasoconstrictors, phenylephrine, and ET-1 (Table 1) , suggesting that rhRLX mainly regulates AngII responsiveness in this artery during pregnancy. The response of the mesenteric artery to vasodilators was not performed as there is no phenotypic difference in responses to ACh and BK between Rln −/− and Rln +/+ mice. It was important to investigate whether or not the improvement in vascular function was associated with changes in circulating sFlt. Therefore, sFlt-1 levels were measured in the plasma of placebo and rhRLXtreated mice. Relaxin treatment did not affect circulating sFlt-1 levels (placebo 15.0 ± 1.5 ng/ml, rhRLX 17.0 ± 2.5 ng/ml; n = 8/genotype). Our lab previously reported unchanged sFlt-1 levels in Rln −/− relative to Rln +/+ mice during pregnancy [28] .
Blocking AngII receptors modulated constriction in the mesenteric artery
To further explore the mechanisms underlying reduced AngIImediated contraction in mesenteric arteries of late-pregnant relaxintreated Rln −/− mice, reactivity to AngII was examined in the absence or presence of AngII receptor blockers ( Figure 2 , Table 1 ). Irbesartan, the AngII (constrictor) AT 1 R antagonist, prevented AngII-induced contraction in the mesenteric artery regardless of treatment (Figure 2A and B, Table 1 ). Interestingly, blocking the AngII (dilator) AT 2 R with the antagonist PD123,319 significantly reduced maximal contraction (P < 0.001) and AUC (P < 0.001) to AngII in the mesenteric artery from placebo-treated mice ( Figure 2C ), but had no effect in arteries of rhRLX-treated mice ( Figure 2D , Table 1 ). These results implicate the AT 2 receptor in mediating the enhanced AngIIinduced contraction of the mesenteric artery in the placebo-treated pregnant Rln −/− mice, an effect that is absent in rhRLX-treated mice.
Investigating endothelium-independent AngII-induced contraction
The influence of the endothelium on AngII-induced contraction was evaluated in the mesenteric arteries from relaxin and placebo-treated late-pregnant Rln −/− mice ( Figure 3 , Table 1 ). Removal of the endothelium had no significant effect on AngII-evoked constriction of the mesenteric artery from placebo-treated ( Figure 3A ) or rhRLXtreated ( Figure 3B ) pregnant mice ( Table 1 ), demonstrating that the rhRLX-mediated reduction in AngII response is independent of the endothelium. Blocking sGC with ODQ had no effect on the contractile response to AngII in placebo or rhRLX-treated Rln −/− mice ( Figure 3C and D) . Removal of the endothelium significantly (P < 0.01) reduced L-NAME-induced contraction in the mesenteric arteries of placebotreated and rhRLX-treated pregnant Rln −/− mice, demonstrating that basal NOS activity is predominantly dependent on the endothelium. Treatment with rhRLX had no effect on basal NOS activity ( Figure 4A ). As reported previously, the hyperresponsiveness to AngII in Rln −/− mice is endothelium independent and associated with a reduction in smooth muscle-derived vasodilator prostanoids [3] . Therefore, we explored the possibility that rhRLX reverses this deficit and stimulates PGI 2 synthesis. Although not a direct measure of vascular PGI 2 production, there was a significant (P = 0.041) increase in circulating levels of the PGI 2 metabolite 6-keto PGF 1α in the rhRLXtreated mice (placebo 55.9 ± 29.7 pg/ml, rhRLX 533.4 ± 218.9 pg/ml) ( Figure 4B ).
rhRLX co-incubation prevents endothelial dysfunction
To explore whether or not TCM induces endothelial dysfunction in mesenteric arteries of virgin mice, arteries were incubated in 50% TCM for 24 h at 37
• C. Fifty per cent TCM had similar levels of sFlt-1 and sEng reported in PE patients [38] [39] [40] (sFlt-1: ∼22 ng/ml, sEng: ∼1 ng/ml). TCM incubation significantly reduced sensitivity (P < 0.0001) and maximum relaxation (P < 0.0001) to ACh (Figure 5A and B; Table 2 ), indicating endothelial dysfunction. There was no evidence of dysfunction of the smooth muscle guanylate cyclase pathway as responses to the endothelium-independent vasodilator SNP were unaffected by treatment (Figure 5C and D; Table 2 ). However, maximal contraction and AUC were both significantly (P = 0.0027, P = 0.0029) increased for AngII-induced contraction following TCM exposure (Figure 5E and F; Table 2) . This study was then repeated using a separate batch of TCM. Mesenteric arteries were incubated in control, TCM+placebo or TCM, and one of three separate concentrations of rhRLX (1, 10, 15 nM) to investigate the ability of rhRLX to prevent endothelial dysfunction ( Figure 6 ). Co-treatment of TCM with placebo or 1 nM rhRLX had no beneficial effect ( Figure 6A ). However, both 10 nM and 15 nM rhRLX restored sensitivity to ACh ( Figure 6C ; Table 2 ), whereas 15 nM also restored maximal relaxation ( Figure 6B and  D) , successfully preventing TCM-induced vascular dysfunction. Responses to AngII and SNP were unaffected by rhRLX treatment (Table 2) .
DISCUSSION
This study demonstrated that in vivo rhRLX treatment for 5 days in late-pregnant Rln −/− mice successfully restored the normal pregnancy-induced attenuation of AngII-mediated vasoconstriction in small mesenteric arteries. In addition, ex vivo incubation of arteries with rhRLX prevented the development of endothelial dysfunction caused by TCM containing high levels of sFlt-1 and sEng. Our data support the idea that rhRLX could be a potential therapeutic agent to alleviate maternal systemic vascular dysfunction associated with hypertensive diseases in pregnant women including PE [13, 41] , through different actions on vascular smooth muscle cells (SMCs) and endothelial cells. In vivo relaxin treatment reversed the enhanced sensitivity of the mesenteric artery to AngII in late-pregnant Rln −/− mice. Although both 3 and 5-day treatments resulted in circulating rhRLX levels comparable to those seen in late pregnancy in wild-type mice [42] , it took 5 days of treatment to recover the phenotype. In male rats, acute and chronic rhRLX treatment results in sustained vasodilatory responses, with the mechanisms responsible dependent on the duration of rhRLX exposure [14, 21] . For example, 2 days of intravenous rhRLX infusion enhanced NOmediated vasodilation, whereas a longer 3-day infusion was required to enhance PGI 2 -mediated vasorelaxation through increased PGI 2 synthesis. In this study, we demonstrated that a longer treatment and higher circulating concentrations of rhRLX were necessary to activate pathways leading to a reduction in responsiveness to AngII. The mesenteric arteries of female Rln −/− mice have compromised smooth muscle-derived PGI 2 production in response to AngIImediated constriction [3] , potentially contributing to the increased response of the mesenteric artery to AngII. Interestingly, our 5-day rhRLX-infused mice had increased circulating 6-keto PGF 1α (stable PGI 2 metabolite) relative to placebo, implying that rhRLX enhances circulating PGI 2 during pregnancy. Therefore, this study supports our initial hypothesis that a lack of circulating relaxin may result in a PGI 2 deficit in the SMCs of the mesenteric artery, resulting in enhanced constriction in response to AngII. AngII-mediated vasoconstriction was abolished by AT 1 R blockade. Interestingly, blockade of AT 2 Rs in arteries from placebotreated pregnant Rln −/− mice reduced AngII-induced contraction, an effect that did not occur in rhRLX-treated mice. These results implicate a disruption to vasodilator AT 2 Rs in the enhanced AngIIinduced contraction of mesenteric arteries in Rln −/− mice. One explanation is that the AT 2 R has switched to mediating a constrictor phenotype, a phenomenon observed in arteries under certain pathophysiological conditions, including those with increased ROS generation. In spontaneously hypertensive rats with enhanced responsiveness to AngII, blockade of AT 2 Rs in iliac and mesenteric arteries significantly reduced contractions [43, 44] . Of relevance to the current study, augmented AngII-induced contraction in subcutaneous arteries of PE patients was also decreased after incubation with PD123,319 [45] . Thus, it is possible in our pregnant Rln −/− mice that activation of AT 2 Rs by AngII leads to vasoconstriction. If this was the case, we would have expected to see AngIImediated constriction after AT 1 R blockade, which did not occur. An Values are mean ± SEM. * = significantly different to TCM + placebo.
alternative explanation might involve post-translational modifications to the AT 2 R. Under normal conditions AT 1 -AT 2 Rs form heterodimers, with AT 2 antagonizing AT 1 , resulting in reduced constriction [46] . In a rat model of PE, AT 1 -AT 2 heterodimer formation was decreased in the renal cortex [47] . Disruption to vasodilator AT 2 Rs in the Rln −/− mice could be due to a similar decrease in AT 1 -AT 2 heterodimer formation. Although our earlier data reported no difference in AT 1 R or AT 2 R gene expression in the mesenteric arteries between the genotypes [3] , it is possible that heterodimer formation is reduced in arteries of Rln −/− mice thereby promoting AngII-induced constriction. This reduction is restored by exogenous rhRLX treatment. Due to the limited availability of mouse mesenteric artery tissue for further analysis, the mechanism by which rhRLX protects against AT 2 R-mediated vasoconstriction to AngII in Rln
mice is yet to be determined. An important finding in our study was that denuding the mesenteric arteries did not affect the response to rhRLX demonstrating that the predominant mode of action is via the vascular SMCs. Relaxin receptors, RXFP1, are localized to both endothelial and vascular SMCs in a variety of vascular beds, including rat and human mesenteric artery [35] . Both NO production and cyclic guanosine monophosphate (cGMP) accumulation increased in isolated bovine aortic SMCs treated with porcine relaxin, associated with enhanced inducible NOS expression and activity [48] . Similarly, rhRLX directly increased cGMP accumulation in human umbilical artery SMCs and indirectly increased cGMP in coronary artery SMCs cocultured with endothelial cells [49] . The latter was inhibited by pre-incubation of the SMCs with the sGC inhibitor ODQ. In the current study, blockade with ODQ had no effect on the denuded mesenteric arteries of either placebo or rhRLX-treated Rln −/− mice.
We conclude that the ability of rhRLX to reduce AII-induced vasoconstriction is endothelium independent and does not involve the sGC-cGMP signaling pathway. The second aspect of our study tested the hypothesis that rhRLX could protect the vasculature from factors capable of causing endothelial dysfunction. An imbalance of circulating sFlt-1 and sEng is thought to contribute to the endothelial dysfunction in the maternal vasculature during PE [9] . Our experimental approach established that a 24 h exposure to 50% TCM with high concentrations of sFlt-1 and sEng caused endothelial dysfunction in small mesenteric arteries from healthy virgin female mice. It is important to note that TCM will contain many other trophoblast cell-derived factors other than sFlt-1 and sEng, which the mesenteric arteries were also exposed to. Co-incubation of these arteries with rhRLX prevented the reduction in ACh-mediated relaxation but not the increase in AngIImediated contraction, providing further evidence that a longer exposure to rhRLX is required to attenuate responses to AngII. Few studies to date have shown that rhRLX treatment protects against endothelial dysfunction in diseased arteries and mechanisms of rhRLX action have only been identified in the aorta [25, 26] . These include reduction of ROS, increased eNOS activity, and restoration of PGI 2 production. Based on these studies and data in healthy rodents, we predict that a combination of mechanisms involving enhanced NO, PGI 2 , and EDH and/or reduction of ROS generation will underpin the vasoprotective actions of rhRLX in our current study.
In conclusion, rhRLX treatment in vivo ameliorates the enhanced responsiveness of small mesenteric arteries to the vasoconstrictor AngII in pregnant Rln −/− mice. These effects are endothelium independent and potentially involve vascular smooth muscle synthesis of PGI 2 . We also provide evidence in a different experimental protocol that ex vivo incubation with rhRLX protects against mesenteric artery dysfunction (reduced endothelium-dependent relaxation) associated with high levels of sFlt-1 and sEng. We also demonstrated that relaxin functions through different vascular pathways (endothelium-dependent and endothelium-independent mechanisms), influenced by duration of relaxin treatment and type of vascular dysfunction. Overall, our data suggest that relaxin is a potential therapeutic to alleviate maternal systemic vascular dysfunction associated with hypertensive diseases in pregnant women.
